Tirzepatide represents a significant breakthrough in the treatment of type 2 diabetes mellitus and/or obesity as the first dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Current analysis of ava... ...
